Hans Pharmaceutical (03692.HK): Application for market approval of Olopatadine injection accepted by the National Medical Products Administration.

Wisdom Financial News App News, Johnson Pharmaceuticals (03692.HK) announced that on June 3, 2026, the company's innovative drug Olaibopeptide injection's New Drug Application (NDA) has been accepted by the National Medical Products Administration (NMPA) of China. It is suitable for long-term weight management in obese or overweight adults. Olaibopeptide is a once-weekly administration glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) dual receptor agonist independently developed by the company.